CSL Seqirus

Privately held: no public share price · Australia

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Bempedoic acid(Nexletol)
Approved
ATP citrate lyaseSmall molecule
Atherosclerotic Cardiovascular Disease
Approved
Alpha- and beta-adrenergic receptors (agonist)Small molecule
Allergic Conditions
Anaphylaxis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Epinephrine · neffyPhase 2Urticaria Chronic
Est. primary completion 2027-06 · NCT06927999 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.